Gender | Age | Menopausal state | Menopausal state Absent
Item
1. women of more than 18 years old (menopausal or not)
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0025320 (UMLS CUI [3])
C0025320 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
Gender | Invasive carcinoma of breast metastatic | Locally advanced breast cancer | Surgery Plan Absent | Indication Tamoxifen | Indication Aromatase Inhibitors
Item
2. women with metastatic invasive breast cancer or locally advanced (without surgical project), for which treatment with tamoxifen or anti aromatase
boolean
C0079399 (UMLS CUI [1])
C0853879 (UMLS CUI [2,1])
C1522484 (UMLS CUI [2,2])
C3495949 (UMLS CUI [3])
C0543467 (UMLS CUI [4,1])
C1301732 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
C3146298 (UMLS CUI [5,1])
C0039286 (UMLS CUI [5,2])
C3146298 (UMLS CUI [6,1])
C0593802 (UMLS CUI [6,2])
In addition to LH-RH Agonist | LH-RH Agonist Absent
Item
+/- lh-rh agonist, is indicated (anti-aromatase prescribed for menopausal womens; tamoxifen prescribed for both menopausal, pre menopausal or not menopausal womens).
boolean
C0332287 (UMLS CUI [1,1])
C1518041 (UMLS CUI [1,2])
C1518041 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Tumor Hormone Expression Estrogen Receptor | Tumor Hormone Expression Progesterone Receptor | Tumor Cell Percentage Immunohistochemistry
Item
3. cancer hormone-expressing estrogen receptor (er) and / or progesterone receptor (pr) (>= 10% of tumor cells by ihc technique).
boolean
C0027651 (UMLS CUI [1,1])
C0019932 (UMLS CUI [1,2])
C0017262 (UMLS CUI [1,3])
C0034804 (UMLS CUI [1,4])
C0027651 (UMLS CUI [2,1])
C0019932 (UMLS CUI [2,2])
C0017262 (UMLS CUI [2,3])
C0034833 (UMLS CUI [2,4])
C0597032 (UMLS CUI [3,1])
C0439165 (UMLS CUI [3,2])
C0021044 (UMLS CUI [3,3])
Neoplasm HER2 Negative
Item
cancer her2 negative.
boolean
C0027651 (UMLS CUI [1,1])
C2348908 (UMLS CUI [1,2])
Evaluable Disease | Measurable Disease | Non-Measurable Lesion
Item
4. evaluable disease (measurable according recist criteria or not)
boolean
C1516986 (UMLS CUI [1])
C1513041 (UMLS CUI [2])
C1334988 (UMLS CUI [3])
Hormone Therapy Adjuvant To be stopped
Item
5. any previous adjuvant hormone therapy should be discontinued for at least 21 days.
boolean
C0279025 (UMLS CUI [1,1])
C1522673 (UMLS CUI [1,2])
C1272691 (UMLS CUI [1,3])
Chemotherapy Quantity Neoplasm Metastasis
Item
6. one or two prior metastatic lines of chemotherapy are allowed
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
WHO performance status scale
Item
7. general status who 0-2
boolean
C1298650 (UMLS CUI [1])
Childbearing Potential Contraceptive methods
Item
8. the women of childbearing age must use an effective contraception for the duration of the study
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Informed Consent
Item
9. informed consent obtained and signed before any specific study procedure
boolean
C0021430 (UMLS CUI [1])
Patient Member National Health Insurance
Item
10. patient member in a national insurance scheme
boolean
C0030705 (UMLS CUI [1,1])
C0680022 (UMLS CUI [1,2])
C0027452 (UMLS CUI [1,3])
Hormone Therapy Pre-existing | Lacking Discontinuation Hormone Therapy Adjuvant
Item
1. patient already treated with hormone therapy or not having stopped the previous adjuvant hormone therapy for at least 21 days.
boolean
C0279025 (UMLS CUI [1,1])
C2347662 (UMLS CUI [1,2])
C0332268 (UMLS CUI [2,1])
C1444662 (UMLS CUI [2,2])
C0279025 (UMLS CUI [2,3])
C1522673 (UMLS CUI [2,4])
Prescription Chemotherapy Breast Carcinoma | Prescription Targeted Therapy Breast Carcinoma | Exception Hormone Therapy
Item
2. prescription of chemotherapy and / or other targeted therapy (other than hormone therapy) for the treatment of the breast cancer
boolean
C0033080 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0678222 (UMLS CUI [1,3])
C0033080 (UMLS CUI [2,1])
C2985566 (UMLS CUI [2,2])
C0678222 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0279025 (UMLS CUI [3,2])
Hormone Therapy Secondary malignant neoplasm of female breast | Hormone Therapy Locally advanced breast cancer
Item
3. any previous hormone therapy for metastatic or locally advanced (without surgical project) breast cancer
boolean
C0279025 (UMLS CUI [1,1])
C0346993 (UMLS CUI [1,2])
C0279025 (UMLS CUI [2,1])
C3495949 (UMLS CUI [2,2])
Hypercalcemia | Status pre- miRNA Dosage | Requirement Diphosphonates
Item
4. known hypercalcaemia before mirna dosage at t=0 requiring immediate biphosphonate therapy
boolean
C0020437 (UMLS CUI [1])
C0332152 (UMLS CUI [2,1])
C1101610 (UMLS CUI [2,2])
C0178602 (UMLS CUI [2,3])
C1514873 (UMLS CUI [3,1])
C0012544 (UMLS CUI [3,2])
Other medical condition Study Subject Participation Status Inappropriate | Mental condition Study Subject Participation Status Inappropriate | Laboratory test result abnormal Severe Study Subject Participation Status Inappropriate | Laboratory test result abnormal chronic Study Subject Participation Status Inappropriate
Item
5. any other medical or psychiatric condition or severe or chronic laboratory abnormality making the the inclusion of the patient in the study inappropriate in the opinion of the investigator.
boolean
C3843040 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1548788 (UMLS CUI [1,3])
C3840291 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C1548788 (UMLS CUI [2,3])
C0438215 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C2348568 (UMLS CUI [3,3])
C1548788 (UMLS CUI [3,4])
C0438215 (UMLS CUI [4,1])
C0205191 (UMLS CUI [4,2])
C2348568 (UMLS CUI [4,3])
C1548788 (UMLS CUI [4,4])
Protocol Compliance Unable
Item
6. patient unable to follow procedures, visits, examinations described in the study.
boolean
C0525058 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
Pregnancy | Breast Feeding
Item
7. pregnant women or nursing mothers will not participate in the study.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Patients Guardianship
Item
8. patients under legal guardianship
boolean
C0030705 (UMLS CUI [1,1])
C0870627 (UMLS CUI [1,2])